Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer
Sponsor: M.D. Anderson Cancer Center
A observational or N/A phase clinical study on Endometrial Clear Cell Adenocarcinoma and Endometrial Dedifferentiated Carcinoma, this trial is actively recruiting participants. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Recruiting
-
May 2025 — Nov 2025 [monthly]
Recruiting
-
Dec 2024 — May 2025 [monthly]
Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
Dec 2023 — Jun 2024 [monthly]
Recruiting
-
Jun 2023 — Dec 2023 [monthly]
Recruiting
-
Sep 2022 — Jun 2023 [monthly]
Recruiting
-
Dec 2021 — Sep 2022 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .